Jill C. Milne
Co-Founder and Chief Executive Officer
Small Molecules Linked to Omega-3 FAs
United States of America
Jill C. Milne, Ph.D., is a co-founder of Catabasis and has served as a member of our board of directors and as our President and Chief Executive Officer since June 2008. Prior to co-founding Catabasis, Dr. Milne worked as head of discovery biology at Sirtris Pharmaceuticals, a biotechnology company, from 2004 to 2008, when it was acquired by GlaxoSmithKline. From 1998 to 2004, Dr. Milne worked at Pfizer Global Research and Development, where she served as the worldwide head of the Drug Pfinder Program and head of the Enzyme Target Group at the Pfizer Discovery Technology Center in Cambridge, Massachusetts. Prior to joining Pfizer, she was an American Cancer Society postdoctoral fellow in the department of biological chemistry and molecular pharmacology at Harvard Medical School from 1995 to 1998. Dr. Milne holds a Ph.D. from Harvard University and a B.A. in biological chemistry from Wellesley College.
Drug discovery, allowing bioactives to reach their targets more efficiently and to have greater efficacy